C 2009, the Authors Journal compilation C 2009, Wiley Periodicals, Inc. DOI: 10.1111/j.1540-8183.2009.00495.x CORONARY ARTERY DISEASE Long-Term Clinical Outcomes and Stent Thrombosis of Sirolimus-Eluting Versus Bare Metal Stents in Patients with End-Stage Renal Disease: Results of Korean Multicenter Angioplasty Team (KOMATE) Registry BYEONG-KEUK KIM, M.D., PH.D., 1 SEUNGJIN OH, M.D., 1 DONG WOON JEON, M.D., 1 JOO YOUNG YANG, M.D., PH.D., 1 JUNG-SUN KIM, M.D., PH.D., 2 SUNGHA PARK, M.D., PH.D., 2 DONGHOON CHOI, M.D., PH.D., 2 YANGSOO JANG, M.D., PH.D., 2 BUM-KEE HONG, M.D., PH.D., 3 HYUK MOON KWON, M.D., PH.D., 3 SEUNG-WHAN LEE, M.D., PH.D., 4 CHOONG WON GOH, M.D., PH.D., 5 KIHWAN KWON, M.D., PH.D., 6 SUNG KEE RYU, M.D., 7 for the Korean Multicenter AngioplastyTeam (KOMATE) Investigators 1 Cardiology Division, Cardiovascular Center of National Health Insurance Corporation Ilsan Hospital, South Korea; 2 Division of Cardiology, Yonsei Cardiovascular Center, Yonsei University College of Medicine, Seoul, South Korea; 3 Department of Internal Medicine, Kangnam Hospital, Yonsei University College of Medicine, Seoul, South Korea; 4 Division of Cardiology, Wonju College of Medicine, Yonsei University, Wonju, South Korea; 5 Division of Cardiology, Inje University Sanggye Paik Hospital, Seoul, Korea; 6 Department of Internal Medicine, Ehwa Womans University Mokdong Hospital, Seoul, South Korea; and 7 Division of Cardiology, Eulji University Hospital, Seoul, South Korea Background: There are still controversies about long-term clinical outcomes of sirolimus-eluting stents (SES) versus bare metal stents (BMS) implantation in patients with end-stage renal diseases (ESRD). Objective: To compare long-term outcomes in patients with (ESRD) following SES versus BMS implantation. Methods: Between March 2003 and July 2005, a total of 54 patients (80 lesions) with ESRD undergoing SES implantation [SES-ESRD] were enrolled and compared with 51 patients (54 lesions) with ESRD receiving BMS during the same periods [BMS-ESRD] in the Korean Multicenter Angioplasty Team Registry. The primary outcome was the composite of death, myocardial infarction (MI), or any stent thrombosis (ST) according to the Academic Research Consortium definition during a 3-year follow-up. Results: The cumulative 3-year rate of composite of death, MI, or ST of the SES-ESRD group (24%) was nearly similar with that of the BMS-ESRD group (24%, P = 1.000). The 3-year rates of death (26% vs. 24%, P = 0.824) or MACE (37% vs. 43%, P = 0.331) in the SES-ESRD did not differ significantly from those in the BMS-ESRD. However, the SES-ESRD showed a sustained lower 3-year TVR rate (9%), compared with BMS-ESRD (24%, P = 0.042). The rate of any ST in SES-ESRD was not significantly higher than that in the BMS-ESRD (17% vs. 14%, P = 0.788). There was no significant difference in the rate of late or very late ST between SES-ESRD (15%) versus BMS-ESRD group (10%, P = 0.557). Conclusions: SES did not increase the risks for death, MI, or any ST in patients with ESRD during the long-term follow-up, compared with BMS. (J Interven Cardiol 2009;22:411–419) Address for reprints: Joo Young Yang, M.D., Ph.D., Cardiology Di- vision, Cardiovascular Center of National Health Insurance Corpo- ration Ilsan Hospital, 1232 Baeksok-dong, Ilsandong-gu, Goyang- si, Gyeonggi-do, 411-719, South Korea. Fax: +82-31-900-0343; e-mail: kbk2565@freechal.com Introduction Sirolimus-eluting stents (SES), compared with bare metal stents (BMS), have been shown to markedly im- prove the short-term clinical outcomes in the complex Vol. 22, No. 5, 2009 Journal of Interventional Cardiology 411